-
1 Comment
e-therapeutics plc is currently in a long term uptrend where the price is trading 3.2% above its 200 day moving average.
From a valuation standpoint, the stock is 44.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 246.2.
Based on the above factors, e-therapeutics plc gets an overall score of 2/5.
Industry | Biotechnology |
---|---|
Sector | Healthcare |
ISIN | GB00B2823H99 |
CurrencyCode | GBP |
Exchange | LSE |
PE Ratio | None |
---|---|
Beta | 0.53 |
Target Price | 10 |
Market Cap | 86M |
Dividend Yield | 0.0% |
e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ETX.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024